Job title: Vice President of Corporate Development
Randy Teel, Ph.D., is Vice President, Corporate Development, and is responsible for Arvinas’ corporate strategy, investor relations, and commercial development functions.
Previously, Dr. Teel was VP and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long-range planning, partnering with the R&D and Commercial organizations as they developed inline and lifecycle management strategies. Dr. Teel also led enterprise risk management and numerous strategic initiatives across the company.
Prior to Alexion, Dr. Teel was an Associate Partner at McKinsey & Company, where he advised biopharmaceutical clients on issues in commercial, medical, and development. He also served numerous other clients in the healthcare industry, including device manufacturers, insurers, and pharmaceutical distributors.
Dr. Teel received a Ph.D in Immunobiology from Yale University and a B.S. in Biology from Gonzaga University.
Panel Discussion 1:50 pm
What are the similarities and differences between traditional drug discovery and TPD during the pre-clinical discovery efforts and clinical studies? Knowing what we know now, if you were to build a team and a strategy on TPD discovery and development from scratch, what changes would you make if any? What are the key translational bottlenecks…Read more
day: Day Two